作者: Luis Martinez-Sobrido , Juan Carlos de la Torre
DOI: 10.1080/14760584.2016.1182024
关键词: Biodefense 、 Virology 、 Arenavirus 、 Ribavirin 、 Viral hemorrhagic fever 、 Viral vector 、 Attenuated vaccine 、 Immunology 、 Lassa virus 、 Biology 、 Viral Vaccine
摘要: ABSTRACTIntroduction: Several arenaviruses, chiefly Lassa virus (LASV), cause hemorrhagic fever (HF) disease in humans and pose significant public health problems their endemic regions. Moreover, HF arenaviruses represent credible biodefense threats. There are not FDA-approved arenavirus vaccines current anti-arenaviral therapy is limited to an off-label use of ribavirin that only partially effective.Areas covered: Live-attenuated (LAV) the most feasible approach control within Different platforms, including recombinant viral vectors expressing LASV antigens, attenuated reassortant have been used develop LAV candidates against with promising results animal models infection, but none them has entered a clinical trial. These vaccine efforts subject recent reviews will be examined this review, which focused on new avenues for development safe effe...